This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

ETANERCEPT (Enbrel; Immunex Corporation; Seattle, Wash) is a biologic response modifier indicated for the reduction in signs and symptoms of moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to 1 or more disease-modifying antirheumatic drugs. The safety and efficacy of etanercept have been assessed in multiple randomized, double-blind, placebo-controlled studies.^1-4 These studies demonstrated a significant response to therapy with etanercept at 3 and 6 months compared with placebo and/or methotrexate. In phase II and phase III clinical trials, injection-site reactions (ISRs) occurred significantly more often and were reported in up to 49% of patients in the etanercept-treated group.^3-4 In this brief report, we evaluate the pathological findings of skin biopsies from an etanercept-associated ISR in a patient with rheumatoid arthritis.

Report of a Case

The patient, a 51-year-old woman with a 14-year history of seropositive, erosive rheumatoid arthritis refractory to combination disease-modifying antirheumatic drug therapy with methotrexate, azathioprine, . . . [Full Text of this Article]

Comment

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Eosinophilic cellulitislike reaction to subcutaneous etanercept injection.
Winfield et al.
Arch Dermatol 2006;142:218-220.
ABSTRACT | FULL TEXT  

Etanercept for Refractory Ocular Sarcoidosis: Results of a Double-Blind Randomized Trial
Baughman et al.
Chest 2005;128:1062-1047.
ABSTRACT | FULL TEXT  

Delayed multiple injection site reaction in a rheumatoid arthritis patient treated with etanercept
Rajakulendran and Deighton
Rheumatology (Oxford) 2004;43:1588-1589.
FULL TEXT  

Recalcitrant, Recurrent Aphthous Stomatitis Treated With Etanercept
Robinson and Guitart
Arch Dermatol 2003;139:1259-1262.
FULL TEXT  

Clinical, Histological, and Immunophenotypic Characteristics of Injection Site Reactions Associated With Etanercept: A Recombinant Tumor Necrosis Factor {alpha} Receptor: Fc Fusion Protein
Zeltser et al.
Arch Dermatol 2001;137:893-899.
ABSTRACT | FULL TEXT  

Anti-Tumor Necrosis Factor {alpha} Therapy in Psoriatic Arthritis and Psoriasis
Girolomoni and Abeni
Arch Dermatol 2001;137:784-785.
FULL TEXT